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Joubert syndrome (JS) is a recessive neurodevelopmental disorder defined by a characteristic 
cerebellar and brainstem malformation recognizable on axial brain MRI as the “Molar Tooth Sign” 
(MTS). Although defined by the neurological features, JS is associated with clinical features affecting 
many other organ systems, particularly progressive involvement of the retina, kidney and liver. JS is 
a rare condition; therefore, many affected individuals may not have easy access to subspecialty 
providers familiar with JS (e.g. geneticists, neurologists, developmental pediatricians, 
ophthalmologists, nephrologists, hepatologists, psychiatrists, therapists and educators). Expert 
recommendations can enable practitioners of all types to provide quality care to individuals with JS 
and know when to refer for subspecialty care. This need will only increase as precision treatments 
targeting specific genetic causes of JS emerge. The goal of these recommendations is to provide a 
resource for general practitioners, subspecialists, and families to maximize the health of individuals 
with JS throughout the lifespan. 
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Introduction 
Joubert syndrome (JS, MIM PS213300) is a recessive neurodevelopmental disorder defined by a 
characteristic cerebellar and brainstem malformation recognizable on axial brain MRI as the “Molar 
Tooth Sign” (MTS).[Joubert and others 1969; Maria and others 1997] This appearance results from a 
combination of abnormalities: cerebellar vermis aplasia/hypoplasia, thick and horizontally-oriented 
superior cerebellar peduncles, and often, a deep interpeduncular fossa. Clinically, individuals with JS 
typically present as infants with hypotonia, abnormal eye movements, respiratory control 
disturbances, and as children or adults, ataxia and/or cognitive impairment.[Doherty 2009; Parisi and 
Glass 1993; Romani and others 2013] In addition to these core features, the majority of individuals 
with JS also have involvement of other body systems including the eye, kidney, liver and 
skeleton.[Bachmann-Gagescu and others 2015a] Therefore, rather than a purely neurological 
condition, JS is a multisystem disorder in which several of the additional features may be progressive, 
thereby substantially complicating medical management. While the diagnosis is often made initially in 
the setting of a neurology, genetics, or developmental pediatrics clinic, the frequent involvement of 
other organ systems means that monitoring for complications is required, with referral to the 
corresponding subspecialists when specific organ involvement is suspected. The purpose of this 
review is to provide management recommendations to minimize medical complications and maximize 
quality of life for individuals with JS. We hope to address a broad audience including families, primary 
care providers and subspecialists, since JS is rare, and few providers have experience with more 
than a handful of affected individuals. 
Given that JS is rare (prevalence estimated at 1/55,000-1/200,000),[Kroes and others 2007; Nuovo 
and others 2019; Parisi and Glass 1993] the present recommendations represent a consensus of 
expert opinion, based on observed outcomes in JS and extrapolation from more common disorders. 
In general, these recommendations focus on the goals of monitoring and treatment without being 
directive as to which medical specialists or techniques are most appropriate, since the availability of 
subspecialists and specific medical technologies varies widely. Some of the evaluations and 
treatments mentioned in these recommendations are not available in all healthcare settings, so we 
try to provide options that will work in a variety of healthcare environments. 
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JS is part of the larger group of disorders called ciliopathies, based on shared genetic causes and 
overlapping phenotypes related to dysfunction of the primary cilium.[Reiter and Leroux 2017] 
Therefore, some of the present recommendations may be useful for individuals with other related 
ciliopathies, in particular nephronophthisis (MIM PS256100), Leber congenital amaurosis (MIM 
PS204000), Senior-Løken syndrome (MIM PS266900), acrocallosal syndrome (MIM 200990), oral-
facial-digital syndromes (MIM PS311200), or MORM (“Mental retardation, truncal Obesity, Retinal 
dystrophy, and Micropenis”) syndrome (MIM 610156). 
Methods 
We reviewed the medical literature from the time of the initial description of JS[Joubert and others 
1969] to the present. The estimated prevalence of features is based on a cohort of >600 individuals 
with JS (“University of Washington (UW) cohort”),[Bachmann-Gagescu and others] an overlapping 
series of 100 individuals with JS evaluated through the intramural National Institutes of Health 
research protocol “Clinical and Molecular Investigations Into Ciliopathies” (ClinicalTrials.gov, 
NCT00068224 – “The NIH cohort”), and the literature. The NIH cohort appears enriched for liver 
involvement and coloboma compared to other cohorts; this may be due to differences in enrollment, 
assessment for clinical features, or other factors. No trials of monitoring strategies or treatments have 
been performed in individuals with JS; therefore, the recommendations below are based on 
professional judgment of the authors and extrapolation from paradigms for similar issues in other 
populations. 
Clinical diagnosis of JS: diagnostic criteria 
For the purpose of this paper, the diagnosis of JS requires the presence of the MTS on axial brain 
MRI (or CT) of optimal quality, including thin sections through the posterior fossa (Fig 1). Despite 
widespread publication of the imaging features of JS, the diagnosis is initially missed in a substantial 
number of individuals, so review by an experienced pediatric neuroradiologist, neurologist, or other 
practitioner with specific knowledge of JS can be critical. In some individuals, the features of the MTS 
are not captured in a single image and must be reconstructed from multiple images. Superior 
cerebellar dysplasia on axial view (Fig 1B), thick, horizontally-oriented superior cerebellar peduncles 
(Fig 1C and 1E) and elevated roof of the 4th ventricle (Fig 1D) on sagittal views, as well as a cleft 
vermis on coronal view (Fig F) can also be helpful. Diffusion tensor imaging has been used to highlight 
deficient midline crossing (decussation) of the superior cerebellar peduncle tracts near the red 
nucleus, which appears to be present in the majority of individuals.[Poretti and others 2007; Widjaja 
and others 2006] Multiple additional brain anomalies have been described in individuals with JS as 
described in the “Neurodevelopmental” section below. 
Not surprisingly, individuals with a subtle MTS or without the full combination of imaging features that 
result in the MTS can still have pathogenic variants in genes associated with JS (unpublished 
observations and [Enokizono and others 2017; Parisi and others 2004; Shaheen and others 2016]). 
The risk of retinal, kidney, and liver involvement in individuals with partial features of JS is unknown.  
In the absence of an appropriate brain MRI, a provisional diagnosis of JS can be made based on 
classic features of hypotonia, developmental delay, ataxia, ocular motor apraxia and respiratory 
rhythm disturbances (tachypnea and/or apnea), along with cerebellar vermis hypoplasia by ultrasound 
or computed tomography imaging. JS is not associated with an easily recognizable facial appearance; 
however, some distinctive facial features, such as a prominent lower jaw, are shared by many 
individuals and can be supportive of the diagnosis.[Braddock and others 2007; Maria and others 1999] 
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Prenatally, the possibility of JS can be raised by cerebellar vermis hypoplasia detected on routine 
ultrasound. Fetal MRI may be helpful in further delineating anomalies identified by ultrasound;[Aslan 
and others 2002; Doherty and others 2005; Fluss and others 2006; Saleem and Zaki 2010] however, 
the typical MTS is often not detected prenatally (unpublished observations). In pregnant women with 
a prior affected child, the finding of definite vermis hypoplasia on ultrasound or MRI can be considered 
diagnostic. In the absence of a family history, the reliability of prenatal diagnosis by imaging is 
unknown; however, a combination of cerebellar vermis hypoplasia with other distinctive JS/ciliary 
features such as polydactyly, or enlarged, cystic, or echogenic kidneys may suggest a JS diagnosis 
even in the absence of a family history.  
The differential diagnosis for JS includes other disorders with anomalies of the posterior fossa such 
as Dandy-Walker malformation, Poretti-Boltshauser syndrome (MIM 615960), and other conditions 
associated with ataxia and/or cerebellar vermis hypoplasia. Many children with JS are first given a 
diagnosis of ocular motor apraxia, or ataxic cerebral palsy before the MTS is identified. The differential 
diagnosis also includes genetically and phenotypically overlapping ciliopathies such as Meckel 
syndrome (MIM PS249000) which likely represents the severe end of a Joubert-Meckel spectrum, 
oral-facial-digital, acrocallosal, Mainzer-Saldino (MIM 266920), COACH (MIM 216360, Cerebellar 
vermis hypo/aplasia, Oligophrenia, Ataxia, ocular Coloboma, and Hepatic fibrosis), or hydrolethalus 
(MIM PS236680) syndromes. For the purpose of this review, we include all individuals with the MTS 
under the umbrella of JS, even if they have other clinical features consistent with other diagnostic 
categories. This includes diagnostic categories such as Joubert Syndrome and Related Disorders 
(JSRD), cerebello-renal syndromes (CORS), as well as subtypes of JS defined by features outside 
the brain such as JS with renal involvement or JS with oral-facial-digital features.[Brancati and others 
2010; Parisi and Glass 2006] In fact, only a minority of people with JS have isolated brain involvement. 
When individuals with JS have atypical clinical features (particularly in consanguineous families), the 
possibility of a second unrelated genetic disorder should be considered and additional genetic testing 
beyond known ciliopathy genes may be warranted. 
Molecular diagnosis of JS 
JS can be caused by pathogenic variants in >35 genes (Table 1). Biallelic pathogenic variants1 in one 
of the known JS-associated genes can be identified in 50-92% of individuals with JS depending on 
the cohort, sequencing method and criteria for causal variants.[Bachmann-Gagescu and others 
2015a; Shaheen and others 2016; Vilboux and others 2017a] In two overlapping cohorts, 5-6 genes 
(AHI1, CC2D2A, CEP290, CPLANE1, KIAA0586, and TMEM67) account for 40-70% of 
families.[Bachmann-Gagescu and others 2015a; Vilboux and others 2017a] Given this substantial 
genetic heterogeneity (i.e. multiple genetic causes for the same phenotype), and the fact that no single 
variant or gene predominates, the most time-efficient and economical means of molecular diagnosis 
can be achieved through next-generation sequencing (NGS) of either a panel of known JS genes, an 
exome (protein coding regions), or a genome (all DNA that can be sequenced). These latter methods 
have the advantage of requiring no specific set-up or updating as additional genes are associated 
with the phenotype.  
For several ethnic groups, initial sequencing for common founder variants may be logical. Specifically, 
the TMEM216 p.R73L variant is common in individuals of Ashkenazi origin and TMEM237 p.R18* is 
common in Hutterites.[Edvardson and others 2010; Huang and others 2011]  In French Canadians, 
several recurring CPLANE1, CC2D2A, and TMEM231 pathogenic variants have been identified, so 
genetic testing can be prioritized by ethnic background;[Srour and others 2012a; Srour and others 
2012b] however, these associations are not sufficient to enable reliable prediction of the genetic cause 
based on the phenotypes, so sequencing of all JS-associated genes by NGS is often preferable. 
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The motivation underlying the identification of a molecular diagnosis, besides confirming the clinical 
diagnosis of JS and providing information regarding recurrence risk/family planning, lies in the known 
gene-phenotype correlations.[Bachmann-Gagescu and others 2015a; Brancati and others 2007; 
Brancati and others 2009; Doherty and others 2010; Vilboux and others 2017a] Indeed, these 
correlations can be used to adjust the frequency of monitoring for progressive features such as retinal 
dystrophy and kidney disease, as described in Tables 3 and 4 and the “Adjusted follow-up 
recommendations based on gene-phenotype associations” section below. Furthermore, it may be 
prudent to avoid nephrotoxic medications in individuals at the highest risk for kidney involvement, 
without unnecessarily restricting these medications in those at low risk. In the future, the genetic 
diagnosis may determine eligibility for specific therapies such as gene-specific medications, antisense 
oligonucleotide treatments, or gene therapy (see “Precision treatments” section below). 
1or hemizygous pathogenic OFD1 variants 
 
System-by-system review of potential clinical issues 
Neurodevelopmental: Essentially all individuals with JS experience hypotonia and motor delays 
during infancy and early childhood, usually evolving to ataxia as they get older. Abnormal eye 
movements and abnormal respiratory control are also seen in most, but may be subtle. Cognition is 
impaired in most, although a minority of individuals have IQs in the normal range.[Bulgheroni and 
others 2016; Fennell and others 1999; Gitten and others 1998; Summers and others 2017] In general, 
adaptive function correlates with cognitive function.[Bulgheroni and others 2016; Summers and others 
2017] However, slowed processing speed is common, so neuropsychological and school evaluations 
should examine both Full Scale Intelligence Quotient (FSIQ) and the Generalized Ability Index (GAI) 
or similar measures to help contextualize the individual’s intellectual abilities. Because the GAI relies 
less on speeded and motor tasks, a more accurate representation of cognitive abilities may be 
ascertained from this or similar scores than from a traditional measure of FSIQ. These studies must 
be interpreted with caution due to potential ascertainment biases (for more or less severely affected 
individuals) and difficulties measuring IQ in the presence of significant motor, communication, and 
visual impairments. Regardless, the range of neurodevelopmental outcome is very broad. Speech 
production is impacted out of proportion to language comprehension due to oral motor 
apraxia.[Braddock and others 2006] Periodic developmental monitoring is required, as well as 
standard therapies (physical, occupational, speech/language) and educational interventions to build 
on areas of strength and target areas of weakness. No specific types of therapy have been shown to 
be more or less effective in this population. Motor issues, particularly the ataxia and the ocular motor 
apraxia, appear to improve as children mature. Most children with JS eventually walk independently, 
although a subset require wheelchairs for some or all mobility.  
 
Multiple additional brain anomalies have been described in individuals with JS,[Bachmann-Gagescu 
and others 2015a; Poretti and others 2017] most commonly cerebellar hemisphere enlargement, 
malrotation of the hippocampi, ventriculomegaly, dysgenesis of the corpus callosum, polymicrogyria, 
heterotopia and occipital encephalocele. While vermis size and abnormal EEG have been associated 
with severity of neurodevelopmental outcome,[Poretti and others 2017; Summers and others 2017] 
no imaging or clinical features can reliably predict neurodevelopmental outcome in a given individual. 
It is suspected that additional major brain malformations, multi-organ involvement, chronic mechanical 
ventilation, and sensory impairments are associated with higher risk of more severely abnormal 
neurodevelopmental outcomes. 
 
Ptosis, strabismus, and abnormal eye movements including nystagmus and ocular motor apraxia are 
neurologically-based vision issues which may be present to some degree in all individuals.[Brooks 
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and others 2018; Khan and others 2008; Sturm and others 2010; Weiss and others 2009] In particular, 
ocular motor apraxia (head thrusting to shift gaze) is characteristic of JS, although it can be seen in 
other conditions. While visual acuity is often normal and eye movements tend to improve with time, 
abnormal smooth pursuit and saccades likely result in some degree of functional visual impairment, 
particularly when objects or the individual’s head are moving.  
 
Seizures have been described in a number of individuals with JS (minimum prevalence 
10%)[Bachmann-Gagescu and others 2015a] and must be specifically sought out during recording of 
the medical history. No single seizure type appears to dominate and there is no evidence to suggest 
that anti-epileptic treatments should differ from those administered to individuals with non-JS 
associated epilepsy. While ventriculomegaly is noted relatively frequently on MRIs of individuals with 
JS, true hydrocephalus requiring treatment is rare. However, since this complication is treatable and 
can have adverse consequences if left untreated, regular monitoring by measurement of head 
circumference is recommended in young children. A small subset of individuals has dystonic 
movements (often facial grimacing) and bite their tongues and cheeks. This is a particularly difficult 
problem, and no successful treatments have been published.[Farmer and others 2006] Apparent 
temperature regulation problems have also been reported including episodic unexplained fevers 
(resulting in infectious disease evaluations) and heat intolerance associated with decreased function 
during hot weather (unpublished observations). The prevalence of these features is unknown. 
 
A variety of behavioral and psychiatric issues have been reported in individuals with JS including 
tantrums, self-injury, autism, depression, anxiety, and auditory hallucinations.[Bachmann-Gagescu 
and others 2015a; Bulgheroni and others 2016; Fennell and others 1999; Summers and others 2017] 
These issues can have an enormous impact on the quality of life for people with JS and their families. 
Parent-reported Child Behavior Checklist (CBCL) data were available for 45/76 individuals who 
received a neuropsychological evaluation at NIH. Scores were elevated across all scales except for 
the externalizing behaviors summary scale (e.g., aggression and tantrums), indicating increased rates 
of behavioral issues compared to the general population.[Summers and others 2017] 
 
Data on psychiatric diagnoses in JS is exceedingly scarce; however, in an Italian cohort of 54 directly-
evaluated individuals, 39% were reported to have behavioral issues, and 7% were diagnosed with 
psychiatric conditions (two with oppositional defiant disorder and two with bipolar 
disorder).[Bulgheroni and others 2016] Within the NIH sample, individuals with JS took psychiatric 
medications at a higher rate than rates reported in typically developing children and adults; however, 
the rate of psychiatric medications in individuals with JS appears to be lower than rates reported in 
other populations with intellectual and developmental disabilities, more generally.[Howie and others 
2014; Jonas and others 2013] Furthermore, within the NIH sample, those with JS who had a greater 
degree of intellectual disability also appear to receive more psychiatric medications.[Summers and 
others 2017] 
 
Circadian rhythm abnormalities and behavioral sleep disturbances have been reported but not 
formally assessed.[Kamdar and others 2011] Additional research is needed to fully delineate the 
spectrum of neurobehavioral and psychiatric issues. Similar to neurobehavioral and psychiatric issues 
in other populations affected by neurodevelopmental conditions, these issues are treated with 
behavioral interventions appropriate for the individual (e.g. parent-child interaction therapy, applied 
behavioral analysis, cognitive-behavioral therapy and other therapies), counseling, and medications 
when necessary. Optimizing the treatment of any medical issues is an essential component of 




Eyes and vision: In addition to the neurologically-based eye issues mentioned above, visual function 
may be impacted by coloboma, retinal dysfunction, optic atrophy, and refractive error. Coloboma 
results from abnormal closure of the optic cup during development, and usually affects the retina or 
optic nerve, but rarely the iris in JS. Typically, colobomata involving the macula or optic nerve cause 
visual impairment. Retinal dysfunction in JS is likely the direct result of problems with the 
photoreceptor outer segment, which is a highly modified cilium. Retinal dystrophy can be apparent at 
birth or lead to progressive decline in vision due to degenerating photoreceptors. Retinal abnormalities 
can be confirmed by an ERG (ElectroRetinoGram) which would show decreased electrical responses 
in the retina, or OCT (Optical Coherence Tomography) which would show abnormal layering of the 
retina with atrophy. Although poorly detailed in the literature, the retinal dystrophy can range from 
congenital retinal blindness diagnosed in infancy (Leber Congenital Amaurosis) to a slowly 
progressive degeneration that can result in nyctalopia (night blindness) or eventual blindness after 
the second decade.[Coene and others 2009] Retinal involvement (defined as abnormal ERG, 
abnormal OCT, and/or abnormal retinal pigment with visual impairment) was present in 30% of 
individuals in the UW cohort, while coloboma was seen in ~17%.[Bachmann-Gagescu and others 
2015a] In the overlapping, directly-evaluated NIH cohort, 24% had retinal dystrophy, 28% had 
coloboma, and 9% had optic nerve atrophy.[Brooks and others 2018] Some genetic causes (e.g. 
CEP290 and AHI1 dysfunction) are more likely to be associated with more severe retinal degeneration 
than others (e.g. INPP5E, MKS1 and NPHP1 dysfunction).  
 
While ptosis is common, it rarely obstructs vision enough to require treatment. Significant refractive 
error (both myopia and hyperopia) have also been reported and can be treated with corrective 
spectacles. Patients with significant (“high”) myopia should be monitored for retinal detachment by 
yearly dilated retinal examination. Strabismus (ocular misalignment) is also common and may lead to 
amblyopia (“lazy eye”), a preventable form of vision loss if caught early enough. Surgical treatment of 
strabismus should be approached with caution, as the strabismus is often variable in JS.[Brooks and 
others 2018] Given the potential overlap with Poretti-Boltshauser syndrome,[Aldinger and others 
2014; Poretti and others 2014] high myopia should prompt a re-review of the MRI for cerebellar 
hemisphere dysplasia, cerebellar cysts, and patchy increased T2/FLAIR signal in the cortical white 
matter, characteristic of Poretti-Boltshauser syndrome. 
 
Loss of visual function may go unrecognized in individuals with cognitive impairment, further limiting 
their developmental potential and interaction with the world; therefore, it is important to assess for 
visual impairment early and provide supportive measures to affected individuals and their families as 
soon as possible. Interventions should aim at improving quality of life. Ideally, a baseline assessment 
for the issues described above would be performed by a pediatric ophthalmologist when JS is 
diagnosed or suspected. Regular follow-up ophthalmological evaluations are warranted for 
surveillance and treatment of the issues described above. 
 
Kidney: Fibrocystic kidney disease develops in 25-30% of individuals, and frequently progresses to 
end-stage renal disease (ESRD).[Bachmann-Gagescu and others 2015a; Fleming and others 2017] 
Of the 29 individuals with kidney involvement in the NIH cohort, 31% had nephronophthisis, 35% had 
an overlap-phenotype of autosomal recessive polycystic kidney disease/nephronophthisis, 10% had 
a unilateral multicystic dysplastic kidney, and 24% had indeterminate-type cystic kidney 
disease.[Fleming and others 2017] Initially, individuals with nephronophthisis may display polyuria 
and polydipsia. Subsets of individuals can present with a kidney phenotype similar to autosomal 
recessive polycystic kidney disease with prenatal onset of enlarged kidneys and early onset 
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hypertension.[Fleming and others 2017; Gunay-Aygun and others 2009] The minimal prevalence for 
ESRD in the UW cohort was 5.1% (n=30/586, 24 received a kidney transplant),[Bachmann-Gagescu 
and others 2015a] while in an overlapping cohort of individuals evaluated directly, the prevalence was 
30% (n=13/97, 11 received a kidney transplant).[Fleming and others 2017] Kidney failure appears to 
be the leading cause of death in JS individuals over 1 year of age, but ESRD has also been observed 
in infants.[Dempsey and others 2017] Anemia is a common clinical finding in those with 
nephronophthisis, often noted to be more severe than expected given the level of kidney dysfunction. 
Poor weight gain or feeding issues can also be associated with kidney dysfunction. While no specific 
treatments to cure or slow the progression of nephronophthisis are currently available, the goals of 
early diagnosis are to maintain quality of life and limit complications of chronic kidney disease (CKD) 
including anemia, bone mineral loss, malnutrition and poor somatic growth. Although not 
systematically evaluated, the risk posed by nephrotoxic medications such as aminoglycosides may 
be increased, so these medications should be avoided when possible. Likewise, non-steroidal anti-
inflammatory drugs (NSAIDs) should be used with caution.  
 
Individuals should be monitored for signs and symptoms of CKD including at least yearly blood 
pressure measurements and laboratory testing for serum electrolytes, calcium, phosphorus, 
creatinine, blood urea nitrogen (BUN), and blood count with hematocrit/hemoglobin. Urine 
concentrating ability may be an effective means of monitoring for CKD in JS. In one study of 93 
individuals with JS, CKD was predicted in >75% with urine osmolality <600 mOsm/kg, and CKD was 
significantly increased in patients with an early diagnosis of isolated urinary concentrating 
defect.[Nuovo and others 2018] Estimated glomerular filtration rate in children [Schwartz and others 
2012] and adults [Levey and others 2009] should be monitored by serum creatinine or creatinine and 
cystatin C when available, since cystatin C may be more accurate in patients with limited muscle 
mass. 
 
Kidney ultrasound may be useful for identifying kidney involvement (altered size, increased 
echogenicity, loss of corticomedullary differentiation, or overt cysts); however, the value of periodic 
kidney ultrasounds for follow-up is unclear, since ultrasonographic appearance does not reflect kidney 
function, which guides medical management. Therefore, we recommend a kidney ultrasound at 
diagnosis to evaluate for genitourinary malformations and establish the presence or absence of kidney 
involvement. It is reasonable to get a second ultrasound during adolescence, and in addition, kidneys 
may be evaluated periodically during the abdominal ultrasounds performed to follow spleen size (see 
below). Follow-up for kidney involvement should rely primarily on history, physical examination and 
blood and urine tests. 
 
Liver: Many individuals with JS have chronically elevated transaminases and GGT (Gamma-glutamyl 
transferase);[Bachmann-Gagescu and others 2015a; Strongin and others 2018; Vilboux and others 
2017a] however, only a small subset of individuals with JS develop hepatic fibrosis severe enough to 
result in portal hypertension. Nonetheless, variceal bleeding can be a serious or even fatal 
complication. In the UW cohort, at least 13 individuals had portal hypertension indicating a minimal 
prevalence of 2% (4 had splenomegaly, 2 had esophageal varices, 6 required a porto-systemic shunt 
and 3 required liver transplantation). In the overlapping NIH cohort, 41% had elevated liver enzymes 
and 13% had probable or definite portal hypertension.[Strongin and others 2018] Potential treatments 
for portal hypertension include banding or sclerosis of esophageal varices to prevent bleeding, porto-




The goal of monitoring is to identify and treat portal hypertension to avoid variceal bleeding. Preferred 
monitoring includes serial platelet measurements looking for a decreasing trend, and serial abdominal 
ultrasounds (every 2-3 years) looking for abnormal increase in spleen size.[Gunay-Aygun and others 
2013] Chronically elevated transaminases and GGT may indicate increased risk for portal 
hypertension.[Strongin and others 2018] Possible gastrointestinal bleeding in individuals with JS must 
be evaluated urgently, with strong consideration of endoscopy to evaluate for esophageal varices. 
Treatment for varices is not JS-specific and can involve sclerotherapy, banding, porto-systemic shunt 
placement, and liver transplantation may be needed in rare cases. 
 
Differing from cirrhosis, the liver disease in JS and other ciliopathies (congenital hepatic fibrosis) does 
not impair the synthetic function of the liver;[Gunay-Aygun and others 1993] therefore, individuals with 
JS do not appear to be at higher risk for complications from hepatotoxic medications, unless they 
have other risk factors such as hepatitis or liver transplantation. All children with JS should receive 
vaccinations against hepatitis A and B. Liver biopsy is generally not indicated in individuals with 
confirmed JS, since the results do not change treatment which is focused on the sequelae of portal 
hypertension. Liver cysts and enlarged intrahepatic bile ducts (e.g. Caroli syndrome), observed in 
other ciliopathies, have not been seen in JS, so the risk for cholangitis does not appear to be 
increased.  
 
Other gastrointestinal complications: A subset of individuals has feeding difficulties, likely due to 
bulbar dysfunction. Aspiration is also frequently reported. Individuals with poor weight gain or 
recurrent infections should be evaluated for swallow dysfunction and aspiration. Treatment can 
include feeding therapy from a speech or occupational therapist, and short- or long-term tube feedings 
may be required. In a large cohort, the minimal prevalence of tube feedings was 10% (8% G-tube and 
2% nasogastric tube).[Bachmann-Gagescu and others 2015a] Drooling can also be a chronic issue 
associated with skin breakdown and social difficulties. Treatments can involve positioning, oral-motor 
therapy, oral medications, and injected botulinum toxin. While a few individuals have been reported 
with JS and Hirschsprung disease (manifested by intractable constipation), this appears to be a rare 
or chance association.[Brancati and others 2010; Ozyurek and others 2008] On the other hand, 
constipation unrelated to Hirschsprung disease is common in JS. Management of constipation should 
therefore first rely on medical measures, and in case of intractable symptoms, evaluation for 
Hirschsprung disease and other causes should be initiated. 
 
Respiratory: Abnormal respiratory control has been clearly documented in infants and children with 
JS by polygraphic recordings, characterized by episodes of apnea, tachypnea and/or 
hyperpnea.[Boltshauser and others 1981; Joubert and others 1969] Abnormal respiratory patterns 
and sleep behaviors have also been described more recently by caregiver report,[Kamdar and others 
2011] and compared to their siblings (unpublished). Although no explicitly documented in the 
literature, our experience indicates that the respiratory control abnormalities improve with age in most 
patients. Nonetheless, in some individuals, respiratory control abnormalities are severe enough to 
warrant chronic ventilation.[Mercado and others 1991] In a retrospective study of individuals with JS 
who had died, apnea and respiratory failure were the leading causes of death in children under 1 year 
of age but were also the cause of death in multiple individuals older than 1 year of age.[Dempsey and 
others 2017] Older children and adults with JS have an increased risk of central and obstructive sleep-
disordered breathing compared to population data, especially if they are obese.[Andermann and 
others 1999; Wolfe and others 2010] Sleep-disordered breathing can also cause or worsen 
neurobehavioral issues,[Witmans and Young 2011] and if untreated, lead to pulmonary hypertension. 
No systematic data exist to guide monitoring, but at a minimum, surveillance should include yearly 
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history and examination for sleep and breathing disturbances. Capillary blood gas and electrolytes in 
younger children and those with obesity can help identify hypoventilation. Sleep medicine consultation 
or polysomnography should be considered for symptomatic individuals. Rare individuals with JS 
additionally have restrictive lung disease due to co-existing skeletal dysplasia such as Jeune 
syndrome.[Halbritter and others 2013; Lehman and others 2010; Shaheen and others 2015; Tuz and 
others 2014] Several male individuals with hemizygous OFD1 variants have been reported to have 
recurrent respiratory infections similar to individuals with primary ciliary dyskinesia (unpublished and 
[Budny and others 2006; Coene and others 2009]); however, additional research is required to 
determine whether individuals with JS are at increased risk for respiratory issues due to abnormal 
mucociliary clearance. Clinicians should consider evaluation for primary ciliary dyskinesia in 
individuals with JS and recurrent respiratory infections. Severely affected individuals are at risk for 
chronic respiratory failure and aspiration pneumonia. 
 
Endocrine: Various endocrinological abnormalities are increased in individuals with JS, such as 
central diabetes insipidus, premature puberty, hypothyroidism, pituitary dysfunction, growth hormone 
deficiency, and/or panhypopituitarism, affecting together 4%.[Bachmann-Gagescu and others 2015a] 
An additional 1-2% have Type I diabetes mellitus, hypothyroidism, polycystic ovarian syndrome, and 
ovarian “failure” which may or may not be increased in JS. Short stature and growth hormone 
deficiency have also been reported;[Bachmann-Gagescu and others 2015a; Stephen and others 
2017; Vilboux and others 2017b] therefore, we recommend closely monitoring for symptoms of 
hypothyroidism, dehydration or fluid overload, poor linear growth, and precocious or delayed pubertal 
development. As noted above, problems with linear growth or polyuria/urinary concentrating defects 
may also be related to kidney involvement. 
 
Musculoskeletal: Similar to other individuals with hypotonia, those with JS have an increased risk for 
scoliosis which is present in at least 5% of individuals;[Bachmann-Gagescu and others 2015a] 
however, it rarely requires treatment. Monitoring for scoliosis by physical examination should be 
performed every 1-2 years until growth is complete. Referral to an orthopedic surgeon is indicated if 
the scoliosis may progress to the point that it causes restrictive respiratory disease, difficulty with 
upright posture, and/or pain. 15% of individuals have polydactyly[Bachmann-Gagescu and others 
2015a] that can be left alone or surgically addressed, depending on the stability of the extra digits, 
difficulty fitting into shoes and gloves, and family preference. In a few families, skeletal dysplasia is 
present in addition to typical JS features, so that a mixed Joubert-Jeune syndrome phenotype is 
observed.[Bachmann-Gagescu and others 2015b; Halbritter and others 2013; Malicdan and others 
2015; Tuz and others 2014] 
 
Cardiovascular: Rare individuals with severe complex congenital heart disease have been reported 
[Karp and others 2012]; however, only 1-2% of individuals have congenital heart disease, including 
atrial septal defect, coarctation of the aorta, bicuspid aortic valve, and aortic stenosis.[Bachmann-
Gagescu and others 2015a] Individuals with murmurs, cyanosis, poor perfusion, and other 
manifestations of possible congenital heart disease should be evaluated by a pediatric cardiologist. 
The utility of a screening echocardiogram has not been evaluated. In the United States, screening all 
newborns for congenital heart disease by physical examination and pulse oximetry is recommended 
as part of standard newborn screening programs.[Oster and others 2016] 
 
Ear, nose and throat: A variety of oral manifestations including tongue hamartomas, additional 
frenulae (under the tongue and between the cheeks and gums), and cleft lip/palate have been 
reported, illustrating the phenotypic overlap between JS and oral-facial-digital syndrome(s).[Poretti 
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and others 2012; Thauvin-Robinet and others 2014] In a small cohort of 22 individuals with JS, 
conductive hearing loss was reported in 6 and mild sensorineural hearing loss was reported in 3, all 
of them older than 17 years of age.[Kroes and others 2010] In contrast, the prevalence of hearing 
loss in a larger cohort was 3%, which is still substantially higher than the 1-2/1000 population 
prevalence in children.[Bachmann-Gagescu and others 2015a; Fortnum and others 2001] No 
systematic data indicate that individuals with JS should be screened for hearing loss differently than 
other individuals; however, it is important to have a low threshold for audiology evaluation, since many 
forms of hearing loss are treatable, and even mild hearing loss can adversely affect speech/language 
development. 
 
Sedation and anesthesia: Individuals with JS may require sedation for a variety of procedures, most 
commonly dental care. Given their known structural abnormalities of the brainstem, central respiratory 
control problems, airway hypotonia and swallow dysfunction, they should be considered high-risk for 
anesthesia. In at least 20 individuals reported in the literature, apnea is a common complication, 
sometimes requiring airway intervention such as intubation or mask airway.[Atalay and others 2016; 
Bhaskar and others 2013; Buntenbroich and Dullenkopf 2013a; Buntenbroich and Dullenkopf 2013b; 
Galante and others 2009; Habre and others 1997; Matthews 1989; Platis and others 2006; Sriganesh 
and others 2010; Sriganesh and others 2014; Vodopich and Gordon 2004] Some authors suggest 
avoiding sedatives known to be associated with central respiratory depression, and avoiding 
unnecessary conscious sedation for brief, uncomplicated procedures such as MRI when possible; 
however, insufficient evidence exists to provide specific guidelines for individuals with JS. To ensure 
timely and appropriate management of potential complications, interventions that require sedation or 
anesthesia should be performed at hospitals equipped to handle any complications that may ensue. 
Individuals with JS should have a pre-anesthesia screening by anesthesia personnel to optimize 
anesthesia outcomes. 
 
Individuals with JS often have complex medical histories, making it imperative for them to be 
evaluated by an anesthesiology professional well in advance of elective sedation or anesthesia. This 
allows time for appropriate clinical evaluation and any required additional testing, ensuring that the 
anesthesiology professional and facility are as prepared as possible. Meeting with the family can also 
help educate the anesthesiology professional about the affected individual and about JS, since it is a 
rare condition and likely not well known to the provider. When anesthesia consultation is not possible 
prior to the procedure, it is imperative to ask for the anesthesia professional to meet the individual 
and the caregiver on the day of surgery. A full health history should be reviewed including medical 
issues, prior anesthetic exposures, and current medications (including any supplements). Allowing a 
caregiver to accompany an affected individual during induction of anesthesia may minimize 
pretreatment with sedatives. In addition, we recommend adherence to procedures for high-risk 
individuals and prolonged observation after sedation to evaluate for apnea. 
Genetic counseling 
Genetic counseling about the mechanism of inheritance, recurrence risk, genetic testing, and 
reproductive options is the standard of care for individuals with JS and their families. To date, only 
autosomal recessive and X-linked inheritance mechanisms have been demonstrated for JS. With 
autosomal recessive inheritance, parents of an affected child have a 25% recurrence risk with each 
pregnancy, and unaffected siblings have a 67% risk of being carriers. Since the carrier frequency for 
any given JS gene in outbred populations is <1/500, the risk of a carrier having an affected child with 
an unrelated partner in out-bred populations is <1/2000. For the one X-linked gene (OFD1), the 
recurrence risk is also 25% (50% of sons); 50% of unaffected daughters are carriers, and all 
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unaffected sons are non-carriers. Recurrence risk counseling in consanguineous and founder 
populations (e.g. Ashkenazi Jews, Hutterites, French Canadians and others) require individualized 
calculations. While little is known about fertility in individuals with JS, several women have had 
children; therefore, teenagers and adults with JS should be counseled about recurrence risk for 
people with rare recessive conditions at a level appropriate to their understanding. Oligogenic 
inheritance, where variants in >1 gene are required to cause a disorder, has been proposed to play a 
role in ciliopathies, [Hoefele and others 2007; Katsanis and others 2001] but no definitive examples 
have been published in JS;[Abu-Safieh and others 2012; Phelps and others 2018] therefore, we 
recommend against clinical counseling for oligogenic inheritance at this time. For details about 
molecular confirmation of the diagnosis, see the “Molecular diagnosis of JS” section above.  
 
Reproductive options for couples with a prior child or fetus affected by JS are best explored through 
formal genetic counseling. Options to reduce the risk of having a second affected child may include 
preimplanation genetic diagnosis for a known pathogenic variant, use of donor egg or sperm, prenatal 
diagnosis through chorionic villus sampling (CVS) or amniocentesis, or adoption. Couples considering 
gamete donation should avoid donation by relatives, given their increased risk of being carriers for 
the same pathogenic variant. For couples in whom the cause is unknown, egg donation may be 
preferred over sperm donation since the mother may be a carrier for a pathogenic OFD1 variant. 
Prenatal imaging such as ultrasound and fetal MRI may be used to evaluate for features of JS during 
pregnancy. Imaging abnormalities may suggest a diagnosis of JS, but the absence of abnormalities 
is not a guarantee that the fetus is unaffected. The decision to pursue or decline alternative 
reproductive options is very personal, and discussion with a geneticist or genetic counselor may 
provide an opportunity to explore all available options. In the United States, genetic counseling 
providers can be identified through the National Society of Genetic Counselors (www.nsgc.org).  
 
Adjusted follow-up recommendations based on gene-phenotype associations 
While general healthcare recommendations apply to all individuals with JS, gene-phenotype 
correlations can be used to adjust management based on the specific underlying genetic etiology. 
CEP290 dysfunction is strongly associated with retinal dystrophy and to a lesser extent kidney 
disease; therefore, individuals with CEP290–related JS should have more frequent monitoring for 
retinal and kidney disease as described above. Similarly, loss of TMEM67 function is strongly 
associated with coloboma and liver fibrosis,[Bachmann-Gagescu and others 2015a; Brancati and 
others 2007; Brancati and others 2009; Doherty and others 2010; Vilboux and others 2017a] 
monitoring for liver fibrosis should be performed more frequently. Weaker associations also support 
a higher risk for retinal disease with AHI1, and kidney disease with TMEM67 and RPGRIP1L. 
Conversely, individuals with loss of TMEM67 function appear less likely to develop retinal disease; 
consequently, less frequent monitoring of retinal involvement may be acceptable in these 
individuals.[Bachmann-Gagescu and others 2015a] 
 
Precision treatments 
Precision treatments are treatments specifically targeting the genetic cause or biological mechanism 
of a disorder. Currently, precision treatments for JS are only available as part of research studies, if 
at all. Although not yet used for targeting a JS gene, direct gene therapy has been used to improve 
visual function for specific types of retinal dystrophy by direct retinal injection of expression vectors in 
humans.[Russell and others 2017] Future trials are likely to involve the CEP290 gene, a major cause 
of Leber congenital amaurosis and JS.[Maeder and others 2019; Mookherjee and others 2018] 
Alternatively, antisense oligonucleotides can augment gene function by blocking aberrant 
splicing[Cideciyan and others 2019; Dulla and others 2018] or by causing exons with deleterious 
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variants to be skipped.[Ramsbottom and others 2018] These treatments are still in early development 
for JS, but have been used for other disorders in humans such as spinal muscular atrophy.[Finkel and 
others 2017] Future medications targeting specific pathways that are disrupted in JS may be 
beneficial, but this work is also in its infancy.[Hynes and others 2014; Kim and others 2018] Some 
promising medications developed for ciliopathy-related conditions in animal models have been 
ineffective or harmful in humans;[Ruggenenti and others 2016; Serra and others 2010; Walz and 
others 2010] therefore, cautious optimism is in order about the timeline for future effective treatments. 
 
Family support 
While caring for a loved one with significant healthcare needs and/or neurodevelopmental disability 
is often very rewarding, it can also be emotionally and cognitively challenging. Families in need can 
draw support from other family members, medical providers, mental health providers, social workers, 
community resources, and family support organizations like the Joubert Syndrome and Related 
Disorders Foundation (https://jsrdf.org), the Asociación de Familias con Síndrome de Joubert y 
Trastornos Relacionados (https://asociacionfabert.wixsite.com/fabert), Associazione Italiana 
Sindrome di Joubert e Atassie Congenite (http://www.aisjac.net), and the Ciliopathy Alliance 
(www.ciliopathyalliance.org). In addition, “respite care” can provide primary caregiver(s) breaks from 
caring for others so that they can rest and care for themselves. Information about respite care 
resources is available from a variety of providers, and at 
https://www.childwelfare.gov/topics/preventing/prevention-programs/respite/ and 




Given the multisystem nature of JS in the majority of individuals, ideal clinical management requires 
careful regular follow-up for early detection and optimal management of complications. To assist 
families in receiving the best medical care possible, one provider should take the lead, performing the 
baseline and follow-up evaluations (Tables 2-4), and referring the individual for specialized care when 
specific organs are involved. In this manner, all the relevant information for a given individual can be 
centralized for coordination of care. In addition to diagnostic, carrier, and prenatal testing, a molecular 
diagnosis allows prognostic sub-stratification that can guide monitoring and treatment of progressive 
features. Moreover, gene-specific treatments may become available in the future and will require the 
knowledge of the gene defect in each individual. 
 
Ongoing research is required to identify all of the genetic causes of JS so that every individual can 
receive a genetic diagnosis and ultimately precision healthcare tailored to that diagnosis. Further 
study of phenotypic outcomes will allow more precise prognostic information, including more accurate 
estimates of the age of onset and long-term evolution for each of the progressive features. In addition, 
less-characterized phenotypic features require systematic assessment, in particular, the behavioral 
and psychiatric issues that often present major problems for the affected individual and their family. 
Finally, existing supportive treatments need to be optimized and precision treatments need to be 
developed and implemented. 
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Figure 1. Diagnostic features of Joubert syndrome on MRI. (A) Molar Tooth Sign (MTS) on T2-
weighted axial images due to the combination of long, thick superior cerebellar peduncles (the roots 
of the tooth) and a deep interpeduncular fossa (the cutting surface of the tooth). This appearance is 
not always captured in a single plane, so it is important to evaluate the MRI as a whole rather than 
relying on a single image. (B) Superior cerebellar foliar dysplasia (bracket) on axial T2-weighted 
images, sometimes seen in the absence of the MTS in individuals carrying pathogenic variants in 
the JS-associated genes (note that the folia at this level are usually shaped like a U or V). (C) 
Horizontally-oriented superior cerebellar peduncle (white arrowhead) on T1-weighted parasagittal 
image; (D) Vermis hypoplasia (outline), elevated roof of the 4th ventricle, and rostrally displaced 
fastigium on T1-weighted sagittal image; (E) Long, thick superior cerebellar peduncles (black 
arrowhead) T2-weighted coronal image; (F) Appearance of a cerebellar cleft (black arrow indicating 
fluid at the cerebellar midline) on T2-weighted coronal image. (A’-F’) similar images from an 





Table 1. Genes associated with Joubert syndrome and risk of complications 
Gene Chr %1 Retina2 Kidney2 Liver2 Other References 
AHI1 6 5-10  - -  [Dixon-Salazar and others 2004; Ferland and others 2004] 
ARL13B 3 <2 - - -  [Cantagrel and others 2008] 
ARL3 10 Unk - - -  [Alkanderi and others 2018] 
ARMC9 2 <2 - - -  [Van De Weghe and others 2017] 
B9D1 17 <2 - - -  [Romani and others 2014] 
B9D2 19 <2 - - -  [Bachmann-Gagescu and others 2015a] 
C2CD3 11 <2 - - - Skeletal dysplasia [Thauvin-Robinet and others 2014] 
CC2D2A 4 5-10 - - -  [Gorden and others 2008] 
CEP104 1 <2 - - -  [Srour and others 2015] 
CEP120 5 Unk - - - Skeletal dysplasia [Roosing and others 2016; Shaheen and others 2015] 
CEP290 12 5-10   - Encephalocele [Sayer and others 2006; Valente and others 2006] 
CEP41 7 <2 - - -  [Lee and others 2012a] 
CPLANE1 5 5-10 - - - PD, OFD [Srour and others 2012b] 
CSPP1 8 2-5 -  -  [Akizu and others 2014; Shaheen and others 2014; Tuz and others 2014] 
FAM149B1  Unk - - - PD, OFD [Shaheen and others 2019] 
HYLS1 11 <2 - - -  [Oka and others 2016] 
IFT172 2 <2 - - - Skeletal dysplasia [Halbritter and others 2013] 
INPP5E 9 2-5 - - -  [Bielas and others 2009] 
KIAA0556 16 <2 - - -  [Sanders and others 2015] 
KIAA0586 14 
2-5 - - -  [Bachmann-Gagescu and others 2015b; Malicdan and others 2015; 
Stephen and others 2015] 
KIAA0753 17 <2 - - -  [Chevrier and others 2016] 
KIF7 15 <2 - - - ACC, PD, Skeletal dysplasia [Dafinger and others 2011; Putoux and others 2011] 
MKS1 17 2-5 - - -  [Romani and others 2014] 
NPHP1 2 <2   -  [Parisi and others 2004] 
OFD1 X <2 - - - Encephalocele, OFD, PCD [Coene and others 2009] 
PDE6D 2 <2 - - -  [Thomas and others 2014] 
PIBF1 13 <2 -  -  [Wheway and others 2015] 
RPGRIP1L 16 2-5 -  -  [Arts and others 2007; Delous and others 2007] 
SUFU 10 Unk - - -  [De Mori and others 2017] 
TCTN1 12 <2 - - -  [Garcia-Gonzalo and others 2011] 
TCTN2 12 <2 -  - Encephalocele, coloboma [Sang and others 2011] 
TCTN3 10 <2 - - -  [Thomas and others 2012] 
TMEM107 17 <2 - - - OFD [Lambacher and others 2016] 
TMEM138 11 <2 - - -  [Lee and others 2012b] 
TMEM216 11 2-5 - - -  [Edvardson and others 2010; Valente and others 2010] 
TMEM231 16 <2 - - -  [Srour and others 2012a] 
TMEM237 2 <2 - - -  [Huang and others 2011] 
TMEM67 8 5-10    Coloboma, PD [Baala and others 2007] 
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1Based on panel sequencing 572 families in the University of Washington cohort 
Abbreviations: ACC = Agenesis of the Corpus Callosum, Chr = Chromosome, OFD = Oral Facial Digital features, PCD = Primary Ciliary Dyskinesia, PD = PolyDactyly, Unk = 
Unknown (not found in the UW cohort) 
2 weak positive association,  strong positive association,  weak negative association, - no known association (all studies to date are underpowered to identify small 
differences in risk associated with less frequent genetic causes) 
 
Note: The following genes are not listed due to lack of sufficient evidence that they are associated with JS (only one family, insufficient clinical information, and/or lack of 
biallelic variants): TTC21B (no biallelic variants in JS, variants reported in families with other ciliopathies),[Davis and others 2011] ZNF423 (one family with possible JS),[Chaki 
and others 2012] CLUAP1 (one family with JS),[Johnston and others 2017] EXOC8 (one family with JS),[Dixon-Salazar and others 2012] CELSR2 (one family in each of two 
papers, variants not reported for one family),[Shaheen and others 2016; Vilboux and others 2017b] POC1B (one family),[Beck and others 2014] CEP164 (one family with JS, 
variants reported in families with other ciliopathies),[Chaki and others 2012; Vilboux and others 2017a] INTU (insufficient imaging informaton in several patients with ciliopathy 


















Table 2. Prevalence, onset and management of medical complications associated with Joubert syndrome 
 Prevalence 
(%)1 
Onset Specialized tests/referrals to 
consider based on 
Hx/PE/routine tests 
Management/ Treatment 
Neurologic     
MTS 100 congenital   
Encephalocele 8 congenital MRI, Neurosurgery consultation Surgery if clinically indicated 
Hydrocephalus rare unknown MRI (or US or CT) if clinically 
indicated, Neurosurgery 
consultation 
Shunt if clinically indicated 
Dystonic episodes rare unknown Neurology consultation Behavioral (remove inciting factors), medications trials, tooth removal for 
severe biting 
Seizures >10 unknown EEG, Neurology consultation Anti-epileptic treatment as required 
Feeding problems 
Dysphagia 
common congenital Video fluoroscopic swallow study  
chest X-ray if s/s 
Feeding therapy, thickened feeds, tube feeding 
Cognitive and 
developmental delays 
common congenital Standardized neurocognitive 
testing (private or school-based), 
annual school program planning2 
Special education support 
Speech therapy, consider alternative communication strategies and/or 
augmentative communication devices 
Occupational Therapy 
Physiotherapy 
Ocular motor apraxia, 
ophthalmoplegia 
~80 congenital Ophthalmology consultation Supportive interventions for visual impairment 









Functional behavioral analysis, 
developmental pediatrics or 
psychiatry consultation, sleep 
medicine evaluation 
Behavioral interventions, medications 
Respiratory     
Abnormal respiratory 
control 
~70 congenital Sleep medicine/pulmonology  
polysomnography 
Respiratory support if indicated, home monitoring controversial, no 
evidence for or against caffeine 
Obstructive apnea unknown neonatal to 
adulthood 




Supplementary oxygen, PAP, T/A, if indicated 
Restrictive lung disease 
(w/ skeletal dysplasia) 
rare congenital Chest X-ray  
Pulmonology consultation 
Respiratory support if indicated, thoracic expansion if indicated 
Ophthalmology+     




Spectacles, patching or pupillary dilation, surgery with caution due to 
underlying neurological abnormality 
Ptosis >19 congenital Ophthalmology consultation Surgery if indicated 
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Retinal dystrophy 30 neonatal to 
adulthood 
Ophthalmology consultation, 
consider OCT, ERG, FAF if 
indicated 
Supportive interventions for visual impairment 
Coloboma 17 congenital Ophthalmology consultation Supportive interventions for visual impairment 




25 neonatal to 
adulthood 
Nephrology consultation 
bone density scan,  
kidney biopsy  
Medications for support of decreasing kidney function; diagnosis and 
treatment of hypertension, prevention of dehydration in early disease and 
fluid overload in late disease; in case of ESKD: dialysis, kidney 
transplantation 








Medications for management of portal hypertension ablation of varices, 
porto-systemic shunting if indicated, liver transplant 
Musculoskeletal     
Polydactyly 15 congenital X-ray, Orthopedics consultation Surgery if indicated for functional or aesthetic reasons 
Scoliosis >5 childhood-
adulthood 
X-ray, Orthopedics consultation Surgery if indicated for respiratory compromise or positioning (rare) 
Skeletal Dysplasia rare congenital X-ray, Skeletal dysplasia 
specialist consultation 
Surgery if indicated for respiratory issues (rare) 
Other     
Endocrine 4-6 infancy to 
adulthood 
Laboratory testing based on 
clinical suspicion 
Hormone replacement as required 
Congenital heart disease rare congenital Echocardiogram, chest X-ray, 
cardiology consultation 
Based on specific lesion 
Hearing loss ~3 neonatal to 
childhood 
Audiology evaluation Ear tubes for chronic otitis media, hearing aids, cochlear implants (rare) 
Cleft palate >3 congenital Craniofacial consultation Surgery if indicated 
Oral features, frenula, 
hamartoma 
>4 congenital NA Surgery if indicated (for function or comfort – rare) 
Feeding difficulty, 
drooling 
common congenital Clinical feeding evaluation, video 
fluoroscopic swallow study 
Feeding therapy, tube feeding, medications for drooling 
Genetics     
Molecular diagnosis NA NA Genetics consultation, genetic 
testing 
Prognostic, recurrence risk, and reproductive counseling,  
Stratification into different risk groups for specific complications,  
Assignment to future gene-specific treatments 
1based on Bachmann-Gagescu, et al. 2015, the prevalence of each feature likely depends on the specific population evaluated 
2Individualized Educational Plan (IEP) in the United States 
Abbreviations: ADHD = Attention Deficit Hyperactivity Disorder, ENT = Ear Nose Throat (Otorhinolaryngology), ESKD = End Stage Kidney Disease, FAF = Fundus Auto-
Fluorescence, Hx = History, mvt = movement, PAP = Positive Airway Pressure (continuous, bilevel or other), PE = Physical Exam, s/s signs and symptoms, T/A = 









History Physical examination 
Neurologic - head 
Consequences of the MTS X X Hypotonia, developmental delay, ataxia Neurological exam 
Encephalocele X  “Bump on head?” (usually occipital) Palpate skull 
Hydrocephalus X X  Increasing head size (<2 yrs), headaches, vomiting OFC plot, fontanelles 
Dystonic episodes X X s/s Muscle tone 
Seizures X X s/s  
Cognition/psychiatric/Behavior 
X X 
Self-injury, Anxiety, Stereotypies, Depression, ADHD, 
Hallucinations 
Std developmental and psychiatric 
assessments, focus on stereotypies, injury 
Eyes 
Consequences of the MTS:  
ocular motor apraxia, 
nystagmus, ophthalmoplegia 
X X 
Head shaking  
Tracking with head mvt 
Focus on eye mvts 
Strabismus X X Eye deviation, head tilt Pupillary alignment, cover-uncover test 
Ptosis 
X X 
Drooping eyelid, chin up position (backward head tilt) Drooping eyelid, chin up position 
(backward head tilt) 
Retinal dystrophy X X Visual impairment particularly in low light, photophobia Visual acuity 
 Coloboma 
X  
Visual impairment (only with macula or optic nerve 
involvement) 
Respiratory 
Consequences of the MTS: 
Abnormal respiratory control 
X X 
Apnea, tachypnea, sleep disordered breathing 
Std pulmonary 
Respiratory rhythm 
(awake and asleep) 
Obstructive apnea 
X X 
Apnea, tachypnea, snoring, sleep disordered 
breathing  
Focus on airway 
Restrictive lung disease (w/ 
skeletal dysplasia) 
X  
Small chest, tachypnea, respiratory distress Std pulmonary 
Kidney 




Growth failure, anemia, polyuria, polydipsia, 2ndary 
enuresis, urinary concentration defect, osteopenia, 
fatigue, decreased appetite, hypertension, 
dehydration/ fluid overload 
Growth parameters, blood pressure, pallor 
Liver 
Congenital Hepatic Fibrosis 
 
X X 
s/s portal hypertension, splenomegaly, varices, GI 
bleeding 
Splenomegaly, spider angiomata (chest, 
arms, neck) 
Musculoskeletal 
Polydactyly X  Functional difficulty Std musculoskeletal 
 Scoliosis X X Change in posture 
Skeletal Dysplasia 
X  







s/s growth failure, hypothyroidism, diabetes mellitus, 
micropenis, abnormal puberty 
Heart rate, blood pressure, growth 
parameters, genital exam 
Congenital heart disease 
X  
Murmur, feeding or exercise intolerance Heart rate, blood pressure (arm and leg), 
oxygen saturation, cardiac exam, consider 
echocardiogram  
Hearing loss X X Delayed speech, decreased response to sounds Newborn and annual hearing screening 
Cleft palate X  Nasal speech, nasal regurgitation, feeding difficulties Std oral 





Abbreviations: ADHD = Attention Deficit Hyperactivity Disorder, MTS = Molar Tooth Sign, mvt = movement, OFC = Occipital-Frontal Circumference, s/s = signs and symptoms, 







































































Abnormal test results reflect involvement 




X   
     
CBC 
X 1-2 X 
anemia Hypersplenism 
(ing plts) 
   
Serum 
electrolytes 
X 1-2 X 







  X 
  Abnormal respiratory 
control, obstructive 




(+cystatin C when 
available) 
X 1-2 X 
CKD     
Ca, Ph, PTH X  X CKD     
Urine osmolality X 1-2 X CKD     
Imaging tests 
Abdominal US1         
Kidney  









    
Liver 
X  X 
 Increased 
echogenicity 
   
Spleen (size) 1 
X 2-3 X 
 Increasing 
spleen size  




X  X 
    Dx confirmation, 
new neurological 
symptoms 
Head CT / US   X     Hydrocephalus 
Chest X-ray  
  X 
  Obstructive apnea/ 
aspiration/pulmonary 
hypertension 
 Skeletal dysplasia 
Specialized tests (requiring referral to specialist) 
Comprehensive 
eye exam 
X 1-2 X 
   Retinal dystrophy, 
coloboma, 
strabismus, 
refractive error,  
amblyopia 
 
OCT / ERG   X    Retinal dystrophy  
Bone 
densitometry 
  X 
CKD     
Upper GI 
endoscopy 
  X 
 Esophageal or 
gastric varices 
   




  X 





X 3 X 
     
1 note that typically, evaluation of spleen size needs to be specifically requested as part of an abdominal ultrasound that will also include evaluation of the liver and kidneys 
* during adolescence 
Abbreviations: ing = increasing over time, ing = decreasing over time, BUN = Blood Urea Nitrogen, Ca = Calcium, CBC = complete blood count, CKD = Chronic Kidney 
Disease, CT = Computed Tomography, ERG = ElectroRetinoGram, GGT = gamma glutamyltranspeptidase, GI = Gastrointestinal, MRI = Magnetic Resonance Imaging, OCT = 
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